Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Analyst Outlook | RBC Capital Markets maintains a $6 price target with an Outperform rating, highlighting pela's potential while acknowledging the speculative nature of the investment |
Financial Tightrope | Despite a healthy current ratio, Oncolytics faces cash burn challenges. Efficient trial designs may help conserve resources as the company advances without immediate partnerships |
Regulatory Tailwinds | FDA's support for progression-free survival as a primary endpoint could accelerate pela's path to market, potentially streamlining the approval process |
Pela's Promise | Oncolytics Biotech's lead candidate, pela, shows potential in metastatic breast cancer and pancreatic cancer, driving speculative interest in this clinical-stage company |
Metrics to compare | ONCY | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCYPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.2x | −4.7x | −0.6x | |
PEG Ratio | −0.12 | 0.03 | 0.00 | |
Price / Book | 9.9x | −4.2x | 2.6x | |
Price / LTM Sales | - | 3.4x | 3.1x | |
Upside (Analyst Target) | - | 156.3% | 53.6% | |
Fair Value Upside | Unlock | −17.0% | 8.0% | Unlock |